CXCL10 and autoimmune diseases

Autoimmunity Reviews

Volumn 8, Issue 5, 2009, Pages 379-383

  Lee, Eun Young ^a   Lee, Zang Hee ^b   Song, Yeong Wook ^a  

^a Seoul National University College of Medicine   (South Korea)

^b School of Dentistry   (South Korea)

Author keywords

Autoimmune disease; CXCL10; RANKL; Rheumatoid arthritis; Systemic lupus erythematosus

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; GAMMA INTERFERON INDUCIBLE PROTEIN 10; OSTEOCLAST DIFFERENTIATION FACTOR;

AUTOIMMUNE DISEASE; BONE DESTRUCTION; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATION; LEUKOCYTE ACTIVATION; MYOSITIS; PROTEIN BINDING; PROTEIN EXPRESSION; RECEPTOR BINDING; REVIEW; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

ANIMALS; ARTHRITIS, RHEUMATOID; CELL MOVEMENT; CHEMOKINE CXCL10; HUMANS; LEUKOCYTES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MYOSITIS; NF-KAPPA B; RANK LIGAND; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; SJOGREN'S SYNDROME; TH1 CELLS;

EID: 61349166620     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2008.12.002     Document Type: Review

References (35)

1. Luster A.D., and Ravetch J.V. Biochemical characterization of a gamma interferon-inducible cytokine (IP-10). J Exp Med 166 (1987) 1084-1097
2. Strieter R.M., Polverini P.J., Kunkel S.L., Arenberg D.A., Burdick M.D., Kasper J., et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 270 (1995) 27348-27357
3. Taub D.D., Lioyd A.R., Conlon K., Wang J.M., Ortaldo J.R., Harada A., et al. Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J Exp Med 177 (1993) 1809-1814
4. Jinquan T., Jing C., Jacobi H.H., Reimert C.M., Millner A., Quan S., et al. CXCR3 expression and activation of eosinophils: role of IFN-gamma-inducible protein-10 and monokine induced by IFN-gamma. J Immunol 165 (2000) 1548-1556
5. Hanaoka R., Kasama T., Muramatsu M., Yajima N., Shiozawa F., Miwa Y., et al. A novel mechanism for the regulation of IFN-γ-inducible protein-10 expression in rheumatoid arthritis. Arthritis Res Ther 5 (2003) R74-R81
6. Narumi S., Takeuchi T., Kobayashi Y., and Konish K. Serum levels of IFN-inducible protein-10 relating to the activity of systemic lupus erythematosus. Cytokine 12 10 (2000) 1561-1565
7. Fujii H., Shimada Y., Hasegawa M., Takehara K., and Kamatain N. Serum levels of a Th1 chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, are elevated in patients with systemic sclerosis. J Dermatol Sci 35 1 (2004) 43-51
8. Sørensen T.L., Tani M., Jesnsen J., Pierce V., Lucchinetti C., Folcik V.A., et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 103 (1999) 807-815
9. Rotondi M., Chiovato L., Romagnani S., Serio M., and Romagnani P. Role of chemokines in endocrine autoimmune diseases. Endocr Rev 28 (2007) 492-520
10. O'Gradaigh D., and Compston J.E. T-cell involvement in osteoclast biology: implications for rheumatoid bone erosion. Rheumatology 43 (2004) 122-130
11. Nanki T., Hayashida K., El-Gabalawy H.S., Suson S., Shi K., Girschick H.J., et al. Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4+ T cell accumulation in rheumatoid arthritis synovium. J Immunol 165 (2000) 6590-6598
12. Ji H., Pettit A., Ohmura K., Ortiz-Lopez A., Duchatelle V., Degott C., et al. Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis. J Exp Med 196 (2002) 77-85
13. Patel D.D., Zachriah H.P., and Whichard L.P. CXCR3 and CCR5 ligands in the rheumatoid arthritis synovium. Clin Immunol 98 (2001) 39-45
14. Kwak H.B., Ha H., Kim H.N., Lee J.H., Kim H.S., Lee S., et al. Reciprocal cross-talk between RANKL and interferon-γ-inducible protein 10 is responsible for bone-erosive experimental arthritis. Arthritis Rheum 58 (2008) 1332-1342
15. Tsubaki T., Takegawa S., Hanamoto H., Arita N., Kamogawa J., Yamamoto H., et al. Accumulation of plasma cells expressing CXCR3 in the synovial sublining regions of early rheumatoid arthritis in association with production of Mig/CXCL9 by synovial fibroblasts. Clin Exp Immunol 141 (2005) 363-371
16. Wedderburn L.R., Robinson N., Patel A., Varsani H., and Woo P. Selective recruitment of polarized T cells expressing CCR5 and CXCR3 to the inflamed joints of children with juvenile idiopathic arthritis. Arthritis Rheum 43 (2000) 765-774
17. Garcia-Lopez M.A., Sanchez-Madrid F., Rodriguez-Frade J.M., Mellado M., Acevedo A., Garcia M.I., et al. CXCR3 chemokine receptor distribution in normal and inflamed tissues. Lab Invest 81 (2001) 409-418
18. Ruth J.H., Rottman J.B., Katschke Jr. K.J., Qin S., Wu L., LaRosa G., et al. Selective lymphocyte chemokine receptor expression in the rheumatoid joint. Arthritis Rheum 44 (2001) 2750-2760
19. Wright L.M., Maloney W., Yu X., Kindle L., Collin-Osdoby P., and Osdoby P. Stromal cell derived factor-1 binding to its chemokine receptor CXCR4 on precursor cells promotes the chemotactic recruitment, development and survival of human osteoclasts. Bone 36 (2005) 840-853
20. Kwak H.B., Lee S.W., Jin H.M., Lee S.H., Takeshita S., Tanaka S., et al. Monokine induced by interferon-gamma is induced by receptor activator of nuclear factor kappa B ligand and is involved in osteoclast adhesion and migration. Blood 105 (2005) 2963-2969
21. Abe M., Hiura K., Wilde J., Moriyama K., Hashimoto T., Ozaki S., et al. Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood 100 (2002) 2195-2202
22. Funauchi M., Ikoma S., Enomoto H., and Horiuchi A. Decreased Th1-like and increased Th2-like cells in systemic lupus erythematosus. Scand J Rheumatol 27 (1998) 219-224
23. Prudhomme G.J., Kono D.H., and Theofilopoulos A.N. Quantitative polymerase chain reaction analysis reveals marked overexpression of interleukin-1 beta, interleukin-10 and interferon gamma mRNA in the lymph nodes of lupus-prone mice. Mol Immunol 32 (1995) 495-503
24. Lit L.C., Wong C.K., Tam L.S., Li E.K., and Lam C.W. Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. Ann Rheum Dis 65 (2006) 209-215
25. Brey R.L., Holliday S.L., Saklad A.R., Navarrete M.G., Hermosillo-Romo D., Stallworth D.L., et al. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 58 (2002) 1214-1220
26. Fragoso-Loyo H., Richaud-Patin Y., Orozco-Narvaez A., Davila-Maldonado L., Atisha-Fregoso Y., Llorente L., et al. Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus. Arthritis Rheum 56 (2007) 1242-1250
27. Wenzel J., Wörenkämper E., Freutel S., Henze S., Haller O., Bieber T., et al. Enhanced type I interferon signaling promotes Th1-biased inflammation in cutaneous lupus erythematosus. J Pathol 205 (2005) 435-442
28. Hasegawa M., Inoue A., Kohno M., Muraoka M., Miyazaki T., Terada M., et al. Antagonist of interferon-inducible protein 10/CXCL10 ameliorates the progression of autoimmune sialadenitis in MRL/lpr mice. Arthritis Rheum 54 (2006) 1174-1183
29. Hasegawa M., Sato S., and Takehara K. Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1 alpha (MIP-1alpha) and MIP-1beta) in patients with systemic sclerosis: MCP-1 and MIP-1alpha may be involved in the development of pulmonary fibrosis. Clin Exp Immunol 117 (1999) 159-165
30. Distler O., Pap T., Kowal-Bielecka O., Meyringer R., Guiducci S., Landthaler M., et al. Overexpression of monocyte chemoattractant protein-1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum 44 (2001) 2665-2678
31. Antonelli A., Ferri C., Fallahi P., Ferrari S.M., Giuggioli D., Colaci M., et al. CXCL10 (α) and CCL2 (β) chemokines in systemic sclerosis-a longitudinal study. Rheumatol 47 (2008) 45-49
32. De Paepe B., De Keyzer K., Martin J.J., and De Bleecker J.L. Alpha-chemokine receptors CXCR1-3 and their ligands in idiopathic inflammatory myopathies. Acta Neuropathol 109 (2005) 576-582
33. Fall N., Bove K.E., Stringer K., Lovell D.J., Brunner H.I., Weiss J., et al. Association between lack of angiogenic response in muscle tissue and high expression of angiostatic ELR-negative CXC chemokines in patients with juvenile dermatomyositis: possible link to vasculopathy. Arthritis Rheum 52 (2005) 3175-3180
34. De Paepe B., Creus K.K., and De Bleecker J.L. Chemokine profile of different inflammatory myopathies reflects humoral versus cytotoxic immune responses. Ann N Y Acad Sci 1109 (2007) 441-453
35. Suzuki F., Nanki T., Imai T., Kikuchi H., Hirohata S., Kohsaka H., and Miyasaka N. Inhibition of CX3CL1 (Fractalkine) improves experimental autoimmune myositis in SJL/J mice. J Immunol 175 (2005) 6987-6996